Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,308
archived clinical trials in
Hepatitis

Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)
A Phase 2a Study of BMS-790052 in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype 1
Status: Enrolling
Updated:  9/23/2015
Metropolitan Research
mi
from
Fairfax, VA
Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)
A Phase 2a Study of BMS-790052 in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype 1
Status: Enrolling
Updated: 9/23/2015
Metropolitan Research
mi
from
Fairfax, VA
Click here to add this to my saved trials
Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)
A Phase 2a Study of BMS-790052 in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype 1
Status: Enrolling
Updated:  9/23/2015
Local Institution
mi
from
Creteil,
Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)
A Phase 2a Study of BMS-790052 in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype 1
Status: Enrolling
Updated: 9/23/2015
Local Institution
mi
from
Creteil,
Click here to add this to my saved trials
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated:  9/23/2015
Alabama Liver & Digestive Specialists (Alds)
mi
from
Montgomery, AL
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated: 9/23/2015
Alabama Liver & Digestive Specialists (Alds)
mi
from
Montgomery, AL
Click here to add this to my saved trials
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated:  9/23/2015
Scripps Clinic
mi
from
La Jolla, CA
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated: 9/23/2015
Scripps Clinic
mi
from
La Jolla, CA
Click here to add this to my saved trials
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated:  9/23/2015
Cli
mi
from
Los Angeles, CA
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated: 9/23/2015
Cli
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated:  9/23/2015
Desta Digestive Disease Medical Center
mi
from
San Diego, CA
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated: 9/23/2015
Desta Digestive Disease Medical Center
mi
from
San Diego, CA
Click here to add this to my saved trials
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated:  9/23/2015
University Of California, San Francisco/Sf General Hospital
mi
from
San Francisco, CA
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated: 9/23/2015
University Of California, San Francisco/Sf General Hospital
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated:  9/23/2015
California Pacific Medical Center
mi
from
San Francisco, CA
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated: 9/23/2015
California Pacific Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated:  9/23/2015
Kaiser Permanente Medical Center
mi
from
San Francisco, CA
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated: 9/23/2015
Kaiser Permanente Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated:  9/23/2015
Transplant Center And Hepatology Clinic, B-154
mi
from
Aurora, CO
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated: 9/23/2015
Transplant Center And Hepatology Clinic, B-154
mi
from
Aurora, CO
Click here to add this to my saved trials
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated:  9/23/2015
Yale University School of Medicine
mi
from
New Haven, CT
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated: 9/23/2015
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated:  9/23/2015
University Of Florida Hepatology
mi
from
Gainesville, FL
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated: 9/23/2015
University Of Florida Hepatology
mi
from
Gainesville, FL
Click here to add this to my saved trials
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated:  9/23/2015
University of Miami
mi
from
Miami, FL
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated: 9/23/2015
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated:  9/23/2015
Miami Research Associates
mi
from
South Miami, FL
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated: 9/23/2015
Miami Research Associates
mi
from
South Miami, FL
Click here to add this to my saved trials
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated:  9/23/2015
Indiana University
mi
from
Indianapolis, IN
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated: 9/23/2015
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated:  9/23/2015
Ochsner Clinic Foundation
mi
from
New Orleans, LA
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated: 9/23/2015
Ochsner Clinic Foundation
mi
from
New Orleans, LA
Click here to add this to my saved trials
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated:  9/23/2015
Mercy Medical Center
mi
from
Baltimore, MD
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated: 9/23/2015
Mercy Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated:  9/23/2015
Digestive Disease Associates, PA
mi
from
Baltimore, MD
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated: 9/23/2015
Digestive Disease Associates, PA
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated:  9/23/2015
Johns Hopkins University
mi
from
Lutherville, MD
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated: 9/23/2015
Johns Hopkins University
mi
from
Lutherville, MD
Click here to add this to my saved trials
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated:  9/23/2015
Claudia T. Martorell, Md, Llc
mi
from
Springfield, MA
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated: 9/23/2015
Claudia T. Martorell, Md, Llc
mi
from
Springfield, MA
Click here to add this to my saved trials
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated:  9/23/2015
James J. Peters VAMC
mi
from
Bronx, NY
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated: 9/23/2015
James J. Peters VAMC
mi
from
Bronx, NY
Click here to add this to my saved trials
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated:  9/23/2015
James Sungsik Park, M.D. C.N.S.C.
mi
from
Great Neck, NY
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated: 9/23/2015
James Sungsik Park, M.D. C.N.S.C.
mi
from
Great Neck, NY
Click here to add this to my saved trials
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated:  9/23/2015
Upper Delaware Valley Infectious Diseases, Pc
mi
from
Monticello, NY
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated: 9/23/2015
Upper Delaware Valley Infectious Diseases, Pc
mi
from
Monticello, NY
Click here to add this to my saved trials
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated:  9/23/2015
University Of North Carolina At Chapel Hill School Of Med
mi
from
Chapel Hill, NC
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated: 9/23/2015
University Of North Carolina At Chapel Hill School Of Med
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated:  9/23/2015
Carolinas Center For Liver Disease
mi
from
Statesville, NC
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated: 9/23/2015
Carolinas Center For Liver Disease
mi
from
Statesville, NC
Click here to add this to my saved trials
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated:  9/23/2015
Options Health Research
mi
from
Tulsa, OK
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated: 9/23/2015
Options Health Research
mi
from
Tulsa, OK
Click here to add this to my saved trials
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated:  9/23/2015
Healthcare Research Consultants
mi
from
Tulsa, OK
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated: 9/23/2015
Healthcare Research Consultants
mi
from
Tulsa, OK
Click here to add this to my saved trials
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated:  9/23/2015
Univ of Pennsylvania
mi
from
Philadelphia, PA
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated: 9/23/2015
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated:  9/23/2015
University Gastroenterology
mi
from
Providence, RI
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated: 9/23/2015
University Gastroenterology
mi
from
Providence, RI
Click here to add this to my saved trials
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated:  9/23/2015
Nashville Medical Research Institute
mi
from
Nashville, TN
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated: 9/23/2015
Nashville Medical Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated:  9/23/2015
The North Texas Research Institute
mi
from
Arlington, TX
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated: 9/23/2015
The North Texas Research Institute
mi
from
Arlington, TX
Click here to add this to my saved trials
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated:  9/23/2015
St. Luke'S Episcopal Hospital - Baylor College Of Medicine
mi
from
Houston, TX
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated: 9/23/2015
St. Luke'S Episcopal Hospital - Baylor College Of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated:  9/23/2015
Alamo Medical Research
mi
from
San Antonio, TX
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated: 9/23/2015
Alamo Medical Research
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated:  9/23/2015
Metropolitan Research
mi
from
Fairfax, VA
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated: 9/23/2015
Metropolitan Research
mi
from
Fairfax, VA
Click here to add this to my saved trials
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated:  9/23/2015
Dean Clinic
mi
from
Madison, WI
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated: 9/23/2015
Dean Clinic
mi
from
Madison, WI
Click here to add this to my saved trials
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated:  9/23/2015
Local Institution
mi
from
Darlinghurst,
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Status: Enrolling
Updated: 9/23/2015
Local Institution
mi
from
Darlinghurst,
Click here to add this to my saved trials
Study of A Combination Pill With GS-7977 and GS-5885 for Hepatitis C in People With HIV
An Open Label Trial to Assess Safety, Tolerability, and Efficacy of the Fixed Dose Combination of GS-7977 and GS-5885 in HCV Genotype 1 Subjects Coinfected With HIV
Status: Enrolling
Updated:  9/24/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Study of A Combination Pill With GS-7977 and GS-5885 for Hepatitis C in People With HIV
An Open Label Trial to Assess Safety, Tolerability, and Efficacy of the Fixed Dose Combination of GS-7977 and GS-5885 in HCV Genotype 1 Subjects Coinfected With HIV
Status: Enrolling
Updated: 9/24/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.
A Phase 3 Evaluation of Daclatasvir Plus Sofosbuvir in Treatment-naïve and Treatment-experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6) Subjects Coinfected With Human Immunodeficiency Virus (HIV)
Status: Enrolling
Updated:  9/24/2015
University of Alabama at Birmingham
mi
from
Birmingham, AL
A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.
A Phase 3 Evaluation of Daclatasvir Plus Sofosbuvir in Treatment-naïve and Treatment-experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6) Subjects Coinfected With Human Immunodeficiency Virus (HIV)
Status: Enrolling
Updated: 9/24/2015
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.
A Phase 3 Evaluation of Daclatasvir Plus Sofosbuvir in Treatment-naïve and Treatment-experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6) Subjects Coinfected With Human Immunodeficiency Virus (HIV)
Status: Enrolling
Updated:  9/24/2015
Pacific Oaks Medical Group
mi
from
Beverly Hills, CA
A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.
A Phase 3 Evaluation of Daclatasvir Plus Sofosbuvir in Treatment-naïve and Treatment-experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6) Subjects Coinfected With Human Immunodeficiency Virus (HIV)
Status: Enrolling
Updated: 9/24/2015
Pacific Oaks Medical Group
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.
A Phase 3 Evaluation of Daclatasvir Plus Sofosbuvir in Treatment-naïve and Treatment-experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6) Subjects Coinfected With Human Immunodeficiency Virus (HIV)
Status: Enrolling
Updated:  9/24/2015
VA Long Beach Healthcare System
mi
from
Long Beach, CA
A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.
A Phase 3 Evaluation of Daclatasvir Plus Sofosbuvir in Treatment-naïve and Treatment-experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6) Subjects Coinfected With Human Immunodeficiency Virus (HIV)
Status: Enrolling
Updated: 9/24/2015
VA Long Beach Healthcare System
mi
from
Long Beach, CA
Click here to add this to my saved trials
A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.
A Phase 3 Evaluation of Daclatasvir Plus Sofosbuvir in Treatment-naïve and Treatment-experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6) Subjects Coinfected With Human Immunodeficiency Virus (HIV)
Status: Enrolling
Updated:  9/24/2015
Anthony M. Mills Md Inc
mi
from
Los Angeles, CA
A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.
A Phase 3 Evaluation of Daclatasvir Plus Sofosbuvir in Treatment-naïve and Treatment-experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6) Subjects Coinfected With Human Immunodeficiency Virus (HIV)
Status: Enrolling
Updated: 9/24/2015
Anthony M. Mills Md Inc
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.
A Phase 3 Evaluation of Daclatasvir Plus Sofosbuvir in Treatment-naïve and Treatment-experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6) Subjects Coinfected With Human Immunodeficiency Virus (HIV)
Status: Enrolling
Updated:  9/24/2015
Peter J. Ruane, MD, Inc.
mi
from
Los Angeles, CA
A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.
A Phase 3 Evaluation of Daclatasvir Plus Sofosbuvir in Treatment-naïve and Treatment-experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6) Subjects Coinfected With Human Immunodeficiency Virus (HIV)
Status: Enrolling
Updated: 9/24/2015
Peter J. Ruane, MD, Inc.
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.
A Phase 3 Evaluation of Daclatasvir Plus Sofosbuvir in Treatment-naïve and Treatment-experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6) Subjects Coinfected With Human Immunodeficiency Virus (HIV)
Status: Enrolling
Updated:  9/24/2015
Jeffrey Goodman Special Care Clinic
mi
from
Los Angeles, CA
A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.
A Phase 3 Evaluation of Daclatasvir Plus Sofosbuvir in Treatment-naïve and Treatment-experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6) Subjects Coinfected With Human Immunodeficiency Virus (HIV)
Status: Enrolling
Updated: 9/24/2015
Jeffrey Goodman Special Care Clinic
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.
A Phase 3 Evaluation of Daclatasvir Plus Sofosbuvir in Treatment-naïve and Treatment-experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6) Subjects Coinfected With Human Immunodeficiency Virus (HIV)
Status: Enrolling
Updated:  9/24/2015
Ucsd Antiviral Research Center (Avrc)
mi
from
San Diego, CA
A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.
A Phase 3 Evaluation of Daclatasvir Plus Sofosbuvir in Treatment-naïve and Treatment-experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6) Subjects Coinfected With Human Immunodeficiency Virus (HIV)
Status: Enrolling
Updated: 9/24/2015
Ucsd Antiviral Research Center (Avrc)
mi
from
San Diego, CA
Click here to add this to my saved trials
A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.
A Phase 3 Evaluation of Daclatasvir Plus Sofosbuvir in Treatment-naïve and Treatment-experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6) Subjects Coinfected With Human Immunodeficiency Virus (HIV)
Status: Enrolling
Updated:  9/24/2015
Whitman Walker Health
mi
from
Washington,
A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.
A Phase 3 Evaluation of Daclatasvir Plus Sofosbuvir in Treatment-naïve and Treatment-experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6) Subjects Coinfected With Human Immunodeficiency Virus (HIV)
Status: Enrolling
Updated: 9/24/2015
Whitman Walker Health
mi
from
Washington,
Click here to add this to my saved trials
A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.
A Phase 3 Evaluation of Daclatasvir Plus Sofosbuvir in Treatment-naïve and Treatment-experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6) Subjects Coinfected With Human Immunodeficiency Virus (HIV)
Status: Enrolling
Updated:  9/24/2015
Capital Medical Associates, PC
mi
from
Washington,
A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.
A Phase 3 Evaluation of Daclatasvir Plus Sofosbuvir in Treatment-naïve and Treatment-experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6) Subjects Coinfected With Human Immunodeficiency Virus (HIV)
Status: Enrolling
Updated: 9/24/2015
Capital Medical Associates, PC
mi
from
Washington,
Click here to add this to my saved trials
A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.
A Phase 3 Evaluation of Daclatasvir Plus Sofosbuvir in Treatment-naïve and Treatment-experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6) Subjects Coinfected With Human Immunodeficiency Virus (HIV)
Status: Enrolling
Updated:  9/24/2015
MedStar Washington Hospital Center
mi
from
Washington,
A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.
A Phase 3 Evaluation of Daclatasvir Plus Sofosbuvir in Treatment-naïve and Treatment-experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6) Subjects Coinfected With Human Immunodeficiency Virus (HIV)
Status: Enrolling
Updated: 9/24/2015
MedStar Washington Hospital Center
mi
from
Washington,
Click here to add this to my saved trials
A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.
A Phase 3 Evaluation of Daclatasvir Plus Sofosbuvir in Treatment-naïve and Treatment-experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6) Subjects Coinfected With Human Immunodeficiency Virus (HIV)
Status: Enrolling
Updated:  9/24/2015
Midway Immunology and Research Center
mi
from
Fort Pierce, FL
A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.
A Phase 3 Evaluation of Daclatasvir Plus Sofosbuvir in Treatment-naïve and Treatment-experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6) Subjects Coinfected With Human Immunodeficiency Virus (HIV)
Status: Enrolling
Updated: 9/24/2015
Midway Immunology and Research Center
mi
from
Fort Pierce, FL
Click here to add this to my saved trials
A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.
A Phase 3 Evaluation of Daclatasvir Plus Sofosbuvir in Treatment-naïve and Treatment-experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6) Subjects Coinfected With Human Immunodeficiency Virus (HIV)
Status: Enrolling
Updated:  9/24/2015
University Of Miami Schiff Center For Liver Diseases
mi
from
Miami, FL
A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.
A Phase 3 Evaluation of Daclatasvir Plus Sofosbuvir in Treatment-naïve and Treatment-experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6) Subjects Coinfected With Human Immunodeficiency Virus (HIV)
Status: Enrolling
Updated: 9/24/2015
University Of Miami Schiff Center For Liver Diseases
mi
from
Miami, FL
Click here to add this to my saved trials
A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.
A Phase 3 Evaluation of Daclatasvir Plus Sofosbuvir in Treatment-naïve and Treatment-experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6) Subjects Coinfected With Human Immunodeficiency Virus (HIV)
Status: Enrolling
Updated:  9/24/2015
Orlando Immunology Center
mi
from
Orlando, FL
A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.
A Phase 3 Evaluation of Daclatasvir Plus Sofosbuvir in Treatment-naïve and Treatment-experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6) Subjects Coinfected With Human Immunodeficiency Virus (HIV)
Status: Enrolling
Updated: 9/24/2015
Orlando Immunology Center
mi
from
Orlando, FL
Click here to add this to my saved trials